Key Takeaways CRSP will report Q3 2025 results, with sales seen at $6.71 million and a$1.32 loss per share.The company holds a positive Earnings ESP and a Zacks Rank #3, hinting at a potential earnings beat.Casgevy's rising sales and pipeline updates on CAR-T and in-vivo candidates will shape investor focus.CRISPR Therapeutics (CRSP) is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is pinn ...